Antengene reports ATG-109 outperforms clinical benchmark in preclinical prostate cancer study

• Antengene presented preclinical results for its AnTenGager-D2 T-cell engager platform at the 2026 Society for Immunotherapy of Cancer annual meeting.
• Platform-based prostate cancer candidate ATG-109 showed stronger preclinical efficacy than a clinical benchmark, with low cytokine release.
• The platform limited tumor-antigen-independent T-cell activation, supporting a wider safety window in preclinical testing.
• Further preclinical studies are planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611081930PR_NEWS_USPR_____CN91050) on November 09, 2026, and is solely responsible for the information contained therein.